Abstract
In the central nervous system, cholinergic and dopaminergic (DA) neurons are among the cells most susceptible to the deleterious effects of age. Thus, the basal forebrain cholinergic system is known to undergo moderate neurodegenerative changes during normal aging as well as severe atrophy in Alzheimer’s disease (AD). Parkinson's disease (PD), a degeneration of nigro-striatal DA neurons is the most conspicuous reflection of the vulnerability of DA neurons to age. Overall, there is growing evidence that a progressive decline in cognitive function and central DA activity represents basic features of normal aging both in humans and laboratory rodents. Spontaneous or environmental neurotoxin-mediated exacerbation of these processes contributes to the symptoms of AD and PD, respectively. In this context, neurotrophic factors that can prevent or delay the decline in cognitive function and central DA activity are of clinical interest. Among them, Insulin-like Growth Factor I and Glial cell line-Derived Neurotrophic Factor are emerging as powerful neuroprotective molecules. This article discusses the experimental evidence supporting the neuroprotective relevance of these and related factors in the aging brain. The availability of induced pluripotent stem cells offers a new promise for the treatment of pathologies associated with the loss of specific cell types as for instance, nigral DA neurons (in PD) or basal forebrain cholinergic neurons (BFCN) in the early stages of AD. Recent studies documenting the use of cell reprogramming for the generation of multipotent neuronal precursors as well as functional BFCN and DA neurons are reviewed.
Keywords: Aging, alzheimer, gene therapy, cell reprogramming, Parkinson, neurodegeneration, neurotropic factors, transdifferentiation.
Current Gene Therapy
Title:Gene Therapy and Cell Reprogramming For the Aging Brain: Achievements and Promise
Volume: 14 Issue: 1
Author(s): Joaquin Pardo, Gustavo R. Morel, Mariana Astiz, Jose I. Schwerdt, Micaela L. Leon, Silvia S. Rodriguez, Claudia B. Herenu and Rodolfo G. Goya
Affiliation:
Keywords: Aging, alzheimer, gene therapy, cell reprogramming, Parkinson, neurodegeneration, neurotropic factors, transdifferentiation.
Abstract: In the central nervous system, cholinergic and dopaminergic (DA) neurons are among the cells most susceptible to the deleterious effects of age. Thus, the basal forebrain cholinergic system is known to undergo moderate neurodegenerative changes during normal aging as well as severe atrophy in Alzheimer’s disease (AD). Parkinson's disease (PD), a degeneration of nigro-striatal DA neurons is the most conspicuous reflection of the vulnerability of DA neurons to age. Overall, there is growing evidence that a progressive decline in cognitive function and central DA activity represents basic features of normal aging both in humans and laboratory rodents. Spontaneous or environmental neurotoxin-mediated exacerbation of these processes contributes to the symptoms of AD and PD, respectively. In this context, neurotrophic factors that can prevent or delay the decline in cognitive function and central DA activity are of clinical interest. Among them, Insulin-like Growth Factor I and Glial cell line-Derived Neurotrophic Factor are emerging as powerful neuroprotective molecules. This article discusses the experimental evidence supporting the neuroprotective relevance of these and related factors in the aging brain. The availability of induced pluripotent stem cells offers a new promise for the treatment of pathologies associated with the loss of specific cell types as for instance, nigral DA neurons (in PD) or basal forebrain cholinergic neurons (BFCN) in the early stages of AD. Recent studies documenting the use of cell reprogramming for the generation of multipotent neuronal precursors as well as functional BFCN and DA neurons are reviewed.
Export Options
About this article
Cite this article as:
Pardo Joaquin, Morel R. Gustavo, Astiz Mariana, Schwerdt I. Jose, Leon L. Micaela, Rodriguez S. Silvia, Herenu B. Claudia and Goya G. Rodolfo, Gene Therapy and Cell Reprogramming For the Aging Brain: Achievements and Promise, Current Gene Therapy 2014; 14 (1) . https://dx.doi.org/10.2174/1566523214666140120121733
| DOI https://dx.doi.org/10.2174/1566523214666140120121733 |
Print ISSN 1566-5232 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Epigenetic Mechanisms in Human Diseases and Gene Therapy
Epigenetic mechanisms including DNA methylation, histone post-translational modifications, non-coding RNAs and chromatin remodeling play crucial roles in gene expression. Aberrant epigenetic changes are often correlated with human diseases and metabolic disorders. Since gene expression can be activated/inactivated by reversible epigenetic mechanisms, increasing studies have been focused on epigenetic regulation in ...read more
Gene- and Cell-Based Therapeutics in Prostate Cancer: Emerging Opportunities and Challenges
Prostate cancer is the second most frequently diagnosed cancer in men worldwide and remains a leading cause of cancer mortality. While advances in androgen receptor–targeted therapies, radioligand treatment, and immunotherapy have improved outcomes, resistance and disease progression continue to present major challenges. Recent breakthroughs in gene and cell therapies — ...read more
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers
Programmed cell death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
The Now and Future of Gene Transfer Technologies
Gene and cell therapies rely on a gene delivery system which is safe and effective. Both viral and non-viral vector systems are available with specific pros and cons. The choice of a vector system is largely dependent on the application which is a balance between target tissue/disease and safety, efficacy ...read more
Related Journals
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
To Be-et, or Not to Be-et, That is the Question: The Role(s) of Nitrate and Nitrite in Health and Illness
Reviews on Recent Clinical Trials Regulation and Quantification of Cellular Mitochondrial Morphology and Content
Current Pharmaceutical Design Assessment of the Antineoplastic Potential of Chalcones in Animal Models
Current Medicinal Chemistry Withdrawal Notice: The Recent Advancement in the Field of Super Paramagnetic Iron Oxide Nanoparticles (SPIONs) for Aiming Breast Cancer
Current Drug Metabolism 1-Cyclohexylpiperazine and 3,3-Dimethylpiperidine Derivatives as Sigma-1 (σ1) and Sigma-2 (σ2) Receptor Ligands: A Review
Central Nervous System Agents in Medicinal Chemistry Functional Role of Glycosphingolipids in Cancer
Current Medicinal Chemistry Role of Mu and Delta Opioid Receptors in Alcohol Drinking Behaviour
Current Drug Abuse Reviews Flavonoids as Anticancer Agents: Recent Progress and State of the Art?
Current Organic Chemistry Molecular Probes for Malignant Melanoma Imaging
Current Pharmaceutical Biotechnology Phosphoinositide 3-Kinases and Leukocyte Migration
Current Immunology Reviews (Discontinued) Trophoblast Invasion: A Possible Link Between Implantation Deficiencies and Preeclampsia
Current Women`s Health Reviews Cancer Proteomics for Cellular Dysfunction: Insights and Trends
Current Pharmaceutical Design Purinergic Receptors and Pain
Current Pharmaceutical Design Therapeutic Strategy of Advanced Hepatocellular Carcinoma by Using Combined Intra-Arterial Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery Synthetic and Biological Vesicular Nano-Carriers Designed for Gene Delivery
Current Pharmaceutical Design Biological and Clinical Significance of Polymorphisms in NAD(P)H: Quinone Oxidoreductase 1 (NQO1)
Current Pharmacogenomics Recovery of Locomotor Function with Combinatory Drug Treatments Designed to Synergistically Activate Specific Neuronal Networks
Current Medicinal Chemistry Ultrasound-Targeted Delivery Technology: A Novel Strategy for Tumor- Targeted Therapy
Current Drug Targets Induction of Antitumor Immune Responses with Recombinant Lentivector: Role of Skin Derived DCs
Current Cancer Therapy Reviews Adenovirus Vectors Composed of Subgroup B Adenoviruses
Current Gene Therapy





